Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction
T Cao, X Zhou, X Wu, Y Zou - Frontiers in Immunology, 2023 - frontiersin.org
The development of immune checkpoint inhibitors (ICIs) has dramatically altered the
landscape of therapy for multiple malignancies, including urothelial carcinoma, non-small …
landscape of therapy for multiple malignancies, including urothelial carcinoma, non-small …
Immune Checkpoint Inhibitor-Induced Psoriasis: Diagnosis, Management, and a Review of Cases
JJ Pach, N Mbonu, S Bhullar, JM Cohen… - Dermatologic …, 2024 - derm.theclinics.com
Immune checkpoint inhibitors (ICIs) have transformed the treatment of cancer. ICIs enhance
antitumor activity by relieving inhibition of T cells responsible for immune surveillance and …
antitumor activity by relieving inhibition of T cells responsible for immune surveillance and …
Plasma proteins and inflammatory dermatoses: proteome-wide Mendelian randomization and colocalization analyses
M Liu, M Chen, J Tan, A Chen, J Guo - Archives of Dermatological …, 2024 - Springer
Current genome-wide association studies (GWAS) of plasma proteomes provide additional
possibilities for finding new drug targets for inflammatory dermatoses. We performed …
possibilities for finding new drug targets for inflammatory dermatoses. We performed …
Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice
LG Popa, C Giurcaneanu, MG Portelli, MM Mihai… - Medicina, 2024 - mdpi.com
Background: New oncologic therapies, including immune checkpoint inhibitors (ICIs), have
revolutionized the survival and prognosis of cancer patients. However, these therapies are …
revolutionized the survival and prognosis of cancer patients. However, these therapies are …